研究单位：[1]Shanghai Orient Hospital[2]Biotheus Inc.[3]Baoji Central Hospital,Baoji,China[4]Baoji Central Hospital,Baoji,China[5]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China[6]Peking University Cancer Hospital,Beijing,China[7]Peking University Cancer Hospital,Beijing,China[8]Jilin Cancer Hospital,Changchun,China[9]The First Hospital of Jilin University,Changchun,China[10]Changde First People's Hospital,Changde,China[11]Hunan Provincial People's Hospital,Changsha,China[12]The First People's Hospital of Changzhou,Changzhou,China[13]Chengdu Integrated TCM& Western Medicine Hospital,Chengdu,China[14]Sichuan Cancer Hospital,Chengdu,China[15]Chongqing Cancer Hospital,Chongqing,China[16]Chongqing Cancer Hospital,Chongqing,China[17]The First Affiliated Hospital of Chongqing Medical University,Chongqing,China[18]The Southwest Hospital of AMU,Chongqing,China[19]Fujian Cancer Hospital,Fuzhou,China[20]Fujian Cancer Hospital,Fuzhou,China[21]Zhejiang Provincial People's Hospital,Hangzhou,China[22]Harbin Medical University Cancer Hospital,Harbin,China[23]Anhui Provincial Hospital,Hefei,China[24]Linyi Cancer Hospital,Linyi,China[25]Jiangsu Province Hospital,Nanjing,China[26]Jiangsu Province Hospital,Nanjing,China[27]Shanghai Orient Hospital,Shanghai,China[28]Shanghai Sixth People's Hospital,Shanghai,China[29]Shengjing Hospital of China Medical University,Shengjing,China[30]Liaoning Cancer Hospital,Shenyang,China[31]The First Hospital of China Medical University,Shenyang,China[32]The People's Hospital of Liaoning Province,Shenyang,China[33]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China[34]Shanxi Bethune Hospital,Taiyuan,China[35]Shanxi Provincial Cancer Hospital,Taiyuan,China[36]Shanxi Provincial Cancer Hospital,Taiyuan,China[37]Taizhou Hospital of Zhejiang Province,Taizhou,China[38]The Second Hospital of Tianjin Medical University,Tianjin,China[39]Hubei Cancer Hospital,Wuhan,China[40]Hubei Cancer Hospital,Wuhan,China[41]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China[42]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,China[43]Xi 'an International Medical Center Hospital,Xi'an,China[44]Xi 'an International Medical Center Hospital,Xi'an,China[45]Yantai Yuhuangding Hospital,Yantai,China[46]Yibin Second People's Hospital,Yibin,China[47]Henan Cancer Hospital,Zhengzhou,China[48]The first affilated hospital of zhengzhou university,Zhengzhou,China[49]The first affilated hospital of zhengzhou university,Zhengzhou,China[50]Zhujiang Hospital of Southern Medical University,Zhujiang,China
研究目的：
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.
